Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers
Authors:
Open Access
- 6 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 16 (6) , 1267-1275
Abstract
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic heart disease characterised by myocardial hypertrophy. HCM can cause outflow tract obstruction, sudden cardiac death and heart failure, but severity is highly variable. In this exploratory cross-sectional study, circulating acylcarnitines were assessed as potential biomarkers in 124 MYBPC3 founder variant carriers (59 with severe HCM, 26 with mild HCM and 39 phenotype-negative [G + P-]). Elastic net logistic regression identified eight acylcarnitines associated with HCM severity. C3, C4, C6-DC, C8:1, C16, C18 and C18:2 were significantly increased in severe HCM compared to G + P-, and C3, C6-DC, C8:1 and C18 in mild HCM compared to G + P-. In multivariable linear regression, C6-DC and C8:1 correlated to log-transformed maximum wall thickness (coefficient 5.01, p = 0.005 and coefficient 0.803, p = 0.007, respectively), and C6-DC to log-transformed ejection fraction (coefficient -2.50, p = 0.004). Acylcarnitines seem promising biomarkers for HCM severity, however prospective studies are required to determine their prognostic value. Graphical abstractKeywords
Funding Information
- Hartstichting (CVON2014-40, 2020B005 DoubleDose, CVON2015-12 e-Detect, Dekker 2015T041)
- UCLH Biomedical Research Centre
- British Heart Foundation (PG/18/5033837, PG/22/10989, Accelerator AA/18/6/34223)
This publication has 52 references indexed in Scilit:
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- Myotonic dystrophy: time for evidence-based therapyEuropean Heart Journal, 2014
- Differences between acylcarnitine profiles in plasma and bloodspotsMolecular Genetics and Metabolism, 2013
- Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic CardiomyopathyCirculation, 2010
- The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screeningEuropean Heart Journal, 2009
- Cardiac Myosin-Binding Protein C Mutations and Hypertrophic CardiomyopathyCirculation, 2009
- Cardiac Myosin Binding Protein CCirculation Research, 2004
- Hypertrophic CardiomyopathyCirculation, 2003
- Can Serum Carnitine Levels Distinguish Hypertrophic Cardiomyopathy From Hypertensive Hearts?Hypertension, 2000